J B Chemicals and Pharmaceuticals , one of India's fastest-growing pharmaceutical companies, has announced strong financial results for the first quarter. The company's performance was marked by significant growth in its domestic business and improved profitability.

Financial Highlights

JB Pharma reported consolidated revenue of ₹1,094.00 crores, representing a 9% increase from ₹1,004.00 crores in the same quarter last year. The company's domestic formulations business was the star performer, recording a 14% year-on-year growth to reach ₹678.00 crores.

Operating EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a substantial increase of 13%, rising to ₹330.00 crores from ₹292.00 crores in the previous year. Notably, the Operating EBITDA margin improved to 30.2%, up from 29.0% in the previous year.

Net profit for the quarter stood at ₹202.00 crores, showing a healthy 14% growth compared to ₹177.00 crores in the same period last year.

Domestic Business Performance

JB Pharma continued to outperform in the Indian Pharmaceutical Market (IPM). According to IQVIA data for MAT June, JB Pharma was the fastest-growing company among the top 25 pharmaceutical companies in India, with a growth rate of 13% compared to the IPM growth of 8%.

The company's domestic business growth was driven by strong performance in both acute and chronic segments, including its ophthalmology portfolio. The chronic portfolio registered a growth of 15%, while the acute portfolio saw a 12% year-on-year increase.

International Business and CDMO

The international business recorded a marginal 2% growth, reaching ₹416.00 crores. While the overall international formulations business saw a slight decline, the Contract Development and Manufacturing Organization (CDMO) segment registered an 8% growth, reaching ₹115.00 crores.

Key Product Performances

Several of JB Pharma's key brands showed strong growth:

• The Razel franchise crossed the ₹100.00 crore mark in MAT June, up from ₹69.00 crores two years prior.
• Azmarda sales reached ₹75.00 crores in MAT June, compared to ₹69.00 crores in the previous year.
• The ophthalmology portfolio demonstrated impressive growth of 19%, reaching ₹57.00 crores.

Management Commentary

Nikhil Chopra, CEO and Whole-time Director of JB Pharma, commented on the results: "JB continues to be the fastest growing domestic pharma company amongst top 25 organizations as per IQVIA MAT Jun data. The domestic business recorded approx. 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well. The CDMO business momentum is likely to sustain in coming quarters."

He added, "Our Operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth. Going forward, we will maintain focus on driving topline growth, cost optimization and organizational efficiencies."

Future Outlook

JB Pharma's management expressed confidence in the company's future performance, with expectations of continued growth in both domestic and CDMO segments. The company's focus on chronic care, ophthalmology, and CDMO opportunities is expected to drive sustainable growth in the coming years.

Corporate Development

In a significant development, JB Pharma announced on June 29 that it has entered into a share purchase agreement with Torrent Pharmaceuticals Limited. Under this agreement, Torrent will acquire a substantial stake in JB Pharma, subject to regulatory approvals. Additionally, the boards of both companies have approved a scheme of amalgamation, which will see JB Pharma merged into Torrent Pharmaceuticals upon receipt of necessary approvals.

JB Pharma's strong quarterly results, coupled with its strategic initiatives and potential merger, position the company for continued growth and success in the pharmaceutical industry.

J B Chemicals and Pharmaceuticals (JB Pharma), one of India's fastest-growing pharmaceutical companies, has reported strong financial results for the first quarter of fiscal year 2026 (Q1 FY26). The company's performance was marked by significant growth in revenue, profitability, and operational efficiency.

Financial Highlights

• Revenue from operations increased by 9% to ₹1,094.00 crore, up from ₹1,004.00 crore in Q1 FY25.
• Operating EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 13% to ₹330.00 crore, compared to ₹292.00 crore in the same quarter last year.
• Net profit rose by 14% to ₹202.00 crore, versus ₹177.00 crore in Q1 FY25.
• Operating EBITDA margin improved to 30.2%, up from 29.0% in the corresponding quarter of the previous year.

Segment Performance

Domestic Formulations

The domestic formulations business was a key driver of growth, recording a 14% year-on-year increase in revenue to ₹678.00 crore. This segment benefited from strong performance in both acute and chronic portfolios, including the ophthalmology division.

International Business

The international business reported a marginal 2% growth, with revenue reaching ₹416.00 crore. While the overall international formulations business saw a slight decline, the Contract Development and Manufacturing Organization (CDMO) segment registered an 8% growth.

Key Product Performances

• The Razel franchise crossed the ₹100.00 crore mark in MAT June'25, up from ₹69.00 crore in MAT June'23.
• Azmarda sales reached ₹75.00 crore in MAT June'25, compared to ₹69.00 crore in MAT June'24.

Market Position and Growth

JB Pharma continues to outperform the Indian Pharmaceutical Market (IPM), maintaining its position as the fastest-growing company among the top 25 pharmaceutical firms in India. According to IQVIA data for MAT June'25, JB Pharma grew at 13% compared to the IPM growth of 8%.

Management Commentary

Nikhil Chopra, CEO and Whole-time Director of JB Pharma, commented on the results: "JB continues to be the fastest growing domestic pharma company amongst top 25 organizations as per IQVIA MAT Jun'25 data. The domestic business recorded approx. 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well. The CDMO business momentum is likely to sustain in coming quarters."

He further added, "Our Operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth. Going forward, we will maintain focus on driving topline growth, cost optimization and organizational efficiencies."

Future Outlook

The management expressed confidence in the company's future performance, with expectations of continued growth driven by the domestic and CDMO segments. JB Pharma aims to maintain its focus on topline growth, cost optimization, and organizational efficiencies to sustain its growth trajectory.

Corporate Development

On June 29, 2025, JB Pharma entered into a share purchase agreement with Torrent Pharmaceuticals Limited and Tau Investment Holdings Pte. Ltd. This agreement involves Torrent acquiring a significant stake in JB Pharma, subject to regulatory approvals. Additionally, the boards of both companies have approved a scheme of amalgamation, which would result in JB Pharma being merged into Torrent Pharmaceuticals.

JB Chemicals & Pharmaceuticals Limited continues to demonstrate strong performance and strategic growth initiatives, positioning itself as a key player in the Indian pharmaceutical industry.